Dr. Vesole on Developing Off-the-Shelf CAR T-Cell Therapy in Multiple Myeloma

Video

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy ​products in multiple myeloma.

David H. Vesole, MD, PhD, director of the Myeloma Program at MedStar Georgetown University Hospital, professor of medicine at Georgetown University, co-director of the Myeloma Division and director of Myeloma Research at John Theurer Cancer Center at Hackensack University Medical Center, discusses the importance of developing off-the-shelf CAR T-cell therapy ​products in multiple myeloma.

CAR T-cell therapy continues to move forward in development ​in multiple myeloma, Vesole explains. Notably, manycompanies are attempting to manufacture BCMA-targeted ​CAR T-cell products. Though, other targets are under investigation as well.

Currently, CAR T-cell products are manufactured using a patient’s ​T cells​, Vesole says. However, this process could take 2 to 4 weeks ​before the product is ready for infusion.

​As such, autologous CAR T-cell therapy has some limitations. Some patients may not be able to wait ​for the product to be made, whereas others may not generate enough T cells ​to be eligible for CAR T-cell therapy. 

​Ongoing research efforts are focused on developing off-the-shelf​, allogeneic CAR T-cell products, which can be administered shortly after the order is placed. Although research is in early stages, the field is hopeful that allogeneic products could provide an alternative option to autologous products for patients with myeloma, Vesole concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.